Table 5.
Mixed linear model to evaluate the impact of total LD kidney function on recipient eGFR
| Parameters | Reduced modela | Multivariable modelb | ||
|---|---|---|---|---|
| Estimate (95% CI) | P value | Estimate (95% CI) | P value | |
| Impact on recipient baseline eGFR, mL/min/1.73 m2 | ||||
| eGFR-dt, per mL/min/1.73 m2 | Changes with each calculation | 0.2 (−0.1 to 0.5) | 0.14 | |
| Recipient variables | ||||
| Age, per year | −0.3 (−0.5 to 0) | 0.04 | −0.2 (−0.4 to 0.1) | 0.20 |
| Female sex, yes vs. no | 4.8 (−3.4 to 13.1) | 0.25 | – | – |
| Preemptive transplantation, yes vs. no | 1.9 (−6.5 to 10.4) | 0.65 | – | – |
| Recipient of a re-transplant, yes vs. no | 6.4 (−6.4 to 19.1) | 0.32 | – | – |
| ABO/HLA incompatible transplantation, yes vs. no | 0.2 (−12.5 to 13) | 0.97 | – | – |
| Sum of HLA mismatch in A, B and DR, per n | −0.7 (−3.4 to 2) | 0.60 | – | – |
| IL-2R antibody induction, yes vs. no | −7 (−20.2 to 6.2) | 0.29 | – | – |
| Tacrolimus-based immunosuppression, yes vs. no | 1.3 (−8.9 to 11.5) | 0.80 | – | – |
| Belatacept-based immunosuppression, yes vs. no | −0.1 (−15.8 to 15.7) | 0.99 | – | – |
| LD variables | ||||
| Age, per year | −0.6 (−1.1 to −0.1) | 0.02 | −0.5 (−1 to 0) | 0.05 |
| Female sex, yes vs. no | −7.1 (−15.3 to 1.1) | 0.09 | −4.6 (−12.8 to 3.7) | 0.28 |
| BMI, per kg/m2 | 0.72 (−0.3 to 1.7) | 0.16 | 0.5 (−0.5 to 1.5) | 0.30 |
| Living-related, yes vs. no | −3.2 (−11.2 to 4.7) | 0.42 | – | – |
| Abnormal MTT of donated kidneyc, yes vs. no | −8.3 (−16 to −0.5) | 0.04 | −6.6 (−14.2 to 0.9) | 0.08 |
| Biopsy-proven rejection | ||||
| TCMR, yes vs. no | 1.4 (−8.4 to 11.3) | 0.77 | −1.3 (−10.7 to 8.1) | 0.78 |
| ABMR, yes vs. no | 0.8 (−11.9 to 13.5) | 0.90 | 1.4 (−10.6 to 13.4) | 0.81 |
| Impact on recipient eGFR slope, mL/min/1.73 m2/year | ||||
| eGFR-dt, per mL/min/1.73 m2 | Changes with each calculation | 0 (−0.1 to 0.1) | 0.52 | |
| Recipient variables | ||||
| Age, per year | 0.1 (0 to 0.2) | 0.21 | 0 (−0.1 to 0.1) | 0.20 |
| Female sex, yes vs. no | −2.2 (−5.3 to 1) | 0.17 | – | – |
| Preemptive transplantation, yes vs. no | 1.3 (−2 to 4.5) | 0.44 | – | – |
| Recipient of a re-transplant, yes vs. no | 0.5 (−4.6 to 5.6) | 0.84 | – | – |
| ABO/HLA incompatible transplantation, yes vs. no | −0.5 (−5.5 to 4.4) | 0.84 | – | – |
| Sum of HLA mismatch in A, B and DR, per n | 0.3 (−0.8 to 1.3) | 0.60 | – | – |
| IL-2R antibody induction, yes vs. no | 1.1 (−3.8 to 6.1) | 0.65 | – | – |
| Tacrolimus-based immunosuppression, yes vs. no | 2.6 (−1.3 to 6.5) | 0.19 | – | – |
| Belatacept-based immunosuppression, yes vs. no | −1 (−6.8 to 4.8) | 0.74 | – | – |
| LD variables | ||||
| Age, per year | −0.1 (−0.3 to 0.1) | 0.18 | −0.2 (−0.4 to 0) | 0.11 |
| Female sex, yes vs. no | 2.7 (−0.4 to 5.9) | 0.09 | 1.0 (−2.2 to 4.3) | 0.53 |
| BMI, per kg/m2 | −0.4 (−0.8 to 0) | 0.03 | −0.4 (−0.8 to 0) | 0.05 |
| Living-related, yes vs. no | −0.3 (−3.3 to 2.8) | 0.87 | – | – |
| Abnormal MTT of donated kidneyc, yes vs. no | 0.6 (−2.4 to 3.6) | 0.70 | 1.0 (−2.0 to 4.0) | 0.53 |
| Biopsy-proven rejection | ||||
| TCMR, yes vs. no | −2.7 (−6.5 to 1) | 0.15 | −1.4 (−5.1 to 2.4) | 0.47 |
| ABMR, yes vs. no | −5.1 (−9.8 to −0.3) | 0.04 | −5.7 (−10.4 to −1.0) | 0.02 |
ABMR antibody-mediated rejection, BMI body mass index, CI confidence interval, eGFR estimated glomerular filtration rate, eGFR-dt total donor eGFR, IL-2R interleukin‑2 receptor, LD live donor, MTT mean transit time, TCMR T cell-mediated rejection
aIn the reduced model recipient eGFR values from 6 to 36 months were used as dependent variable. eGFR-dt and time were included in each calculation. Other variables were added one by one. Slope estimates additionally considered interactions of variables with time
bThe multivariable model included eGFR-dt and time. Additionally, the model was expanded by variables with a P value of <0.157 for their impact on recipient baseline eGFR or its slope in the reduced model
cMTT values of 1.9–2.9 min were considered normal